Ho Maykin
- SEC CIK
- 0001646395
No open-market purchases or sales filed in the past year.
Current role at each company
- AGIO Agios Pharmaceuticals, Inc.Directoras of Jun 23, 2026
- KYNB Kyntra Bio, Inc.Directoras of Jun 17, 2026
- BMRN Biomarin Pharmaceutical IncDirectoras of Jun 4, 2026
- NMRA Neumora Therapeutics, Inc.Directoras of May 29, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Ho Maykin as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
KYNB Kyntra Bio, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 9, 2023 (view filing) | Jun 8 | 1 day | Ho MaykinDirector | SSale | −8.52K | $17.44 | −$148.6K | −21.3%31.5K after | 2 lots10b5-1 |